[心力衰竭中麻醉的外科手术管理]
Carla Klapproth1, Martin Bender2, Tobias Ninke2
1LMU Klinik für Anästhesiologie, München, Deutschland. Carla.Klapproth@med.uni-muenchen.de.
Die Anaesthesiologie
|November 19, 2025
概括
在手术前管理心力衰竭对于降低手术风险至关重要. 仔细评估,药物调整和量身定制的麻醉是改善心力衰竭患者接受手术结果的关键.
科学领域:
- 心脏病学 心脏病学
- 麻醉学 麻醉学
- 在外科手术期间的医学.
背景情况:
- 心力衰竭是术后并发症和术后死亡的重要危险因素.
- 术前评估对于识别和管理心力衰竭患者至关重要.
研究的目的:
- 概述在心力衰竭患者中优化术后管理的策略.
- 强调多学科方法和量身定制的麻醉护理的重要性.
主要方法:
- 在手术前咨询期间详细的病史和体检.
- 根据需要评估心脏生物标志物,铁状况和心声回声仪.
- 针对急性失补偿患者的跨学科讨论,涉及选择性手术前的条件补偿.
主要成果:
- 术前心脏药物调整或暂停是必要的.
- 适当的监测有助于分化麻醉的诱导,管理和术后护理.
- 在手术期间的治疗包括维持正常血压,适当的体积管理和量身定制的甲醇胺治疗.
结论:
- 优化心力衰竭的术前评估和管理可以减轻术后风险.
- 对麻醉和外科手术周护的全面,个性化的方法对于改善患者的治疗结果至关重要.
相关概念视频
Cardiomyopathy VII: Pre and Post Operative Nursing Management
248
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
248
Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
Heart Failure VII: Nursing Interventions
389
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
389
Heart Failure VI: Adjunct Therapies
228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
Heart Failure Drugs: β-Blockers
724
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
724


